In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations

Targets: Doravirine is a just lately licensed HIV-1 NNRTI with improved efficacy, pharmacokinetics and security profile in contrast with efavirenz and restricted cross-resistance with rilpivirine and

by Frank Green9 Min Reading